A Study to Collect Clinical Data, Blood Samples, and Tissue Specimens from Patients with Metastatic Breast Cancer
About this study
The primary objective of this study is to create a comprehensive registry that includes patient demographics, clinical and histopathological data, blood samples, and tissue specimens from the primary tumor and metastatic sites of patients with metastatic breast cancer to improve our understanding of the mechanisms of tumor metastasis and therapeutic resistance.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
- Histologically confirmed or suspected invasive breast cancer
- Radiographic evidence of distant metastatic disease
- Clinical or radiographic evidence of disease progression OR presenting with de novo stage IV disease
- Available archived tissue from the initial breast primary (formalin fixed paraffin embedded [FFPE] tissue is acceptable; fresh frozen tissue is preferred if available)
- Accessible lesion representative of recurrent or metastatic breast cancer for biopsy
- Type 1 specimen collection: Patients undergoing a clinically directed tissue biopsy or tissue collection who are willing to have additional specimens taken for research during the same procedure. Sites for tissue acquisition may include the breast, skin/chest wall, lymph node/soft tissue, liver, bone, lung, brain, pleural fluid, and ascites as needed for routine clinical care.
- Type 2 specimen collection: Patients underging a tissue biopsy or tissue collection for research purposes only. Sites for tissue acquisition include the breast, skin/chest wall, lymph node/soft tissue, liver, bone, pleural fluid, and ascites. Research directed lung biopsies and brain biopsies are not permitted. Procedures for tissue acquisition are restricted to those performed under local anesthesia or IV conscious sedation; biopsies that require general anesthesia are not permitted in this situation.
- Previous cytologic confirmation of malignant pleural effusion or ascites if that is the planned source of fresh specimen collection for study participation
- Age 18 years or older
- ECOG performance status 0-2
- Ability to understand and the willingness to sign an informed consent document
- Concurrent disease or condition that in the opinion of the treating oncologist or the provider performing the biopsy procedure renders the patient inappropriate for study participation
- Concurrent serious medical or psychiatric disorder that may interfere with the subject’s safety during the biopsy or tissue collection procedure
- Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent
- History of a serious or life-threatening allergic reaction to local anesthetics (e.g., lidocaine, xylocaine) used during a biopsy procedure
- Pregnancy (due to the risk of conscious sedation or anesthesia to mother and fetus)
- Any condition or laboratory finding that in the opinion of the treating oncologist or the provider performing the biopsy procedure would make participation in this protocol hazardous for the patient
Participating Mayo Clinic locations
Study statuses change often. Please contact us for help.
|Mayo Clinic Location
Mayo Clinic principal investigator
Minetta Liu, M.D.
Contact us for the latest status
Minetta Liu M.D.
This study has completed enrollment of targeted participants and currently is completing research activities including study intervention, specimen collection, testing and data analysis.
Publications are currently not available
Study Results Summary
Not yet available
Supplemental Study Information
Not yet available